Strategic Focus Clinical-stage gene editing specialist with LEAPER-based in vivo RNA editing and ex vivo hematopoietic stem cell and T cell platforms, presenting opportunities for collaboration or partnerships in advanced gene therapies and translational studies.

Collaborations Network History of academic and industry collaborations (UW-Madison, Peking Union Medical College Hospital, Haihe Laboratory) signals openness to co-development and sponsored research opportunities, ideal for joint programs or sponsored trials.

Non-Human Primate Validation Recent NHP disease model advancements and preclinical POC data for LEAPER 2.0 presented at ASGCT indicate a mature preclinical program and potential for CRO or consulting engagements to support translational studies or IND readiness.

Funding and Growth Significant funding backing (Series B+ around $62.6M) and revenue in the mid seven figures position the company as a growth-focused partner with budget for collaboration, technology licensing, or platform access arrangements.

Platform Commercial Relevance Proprietary platforms spanning RNA base editing, ex vivo gene editing, and allogeneic CAR-T offer multiple entry points for technology licensing, co-development, or contract research services aligned with clients seeking next-generation gene-editing solutions.